MK-3475 + INCB024360
Phase 1/2CompletedDevelopment Stage
Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC)
Jul 17, 2014 → Nov 6, 2020
About MK-3475 + INCB024360
MK-3475 + INCB024360 is a phase 1/2 stage product being developed by Merck for Microsatellite-instability (MSI) High Colorectal Cancer (CRC). The current trial status is completed. This product is registered under clinical trial identifier NCT02178722. Target conditions include Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02178722 | Phase 1/2 | Completed |